New options for treatment of candidaemia in critically ill patients

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 4, 2008, Pages 46-54

  Ruhnke, M ^a   Hartwig, K ^a   Kofla, G ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Antifungal agents; Azoles; Candidaemia; Echinocandins; Liposomal amphotericin B; Review; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MYCOGRAB; PLACEBO; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ABNORMAL LABORATORY RESULT; ANTIFUNGAL SUSCEPTIBILITY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRITICALLY ILL PATIENT; CRYPTOCOCCOSIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; GRANULOCYTOPENIA; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LOADING DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; ISSATCHENKIA ORIENTALIS;

EID: 42649110047     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.01981.x     Document Type: Review

References (44)

1. GS Martin DM Mannino S Eaton M Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
2. D Pittet N Li RF Woolson RP Wenzel Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model Clin Infect Dis 24 1997 1068 1078
3. O Gudlaugsson S Gillespie K Lee Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 37 2003 1172 1177
4. J Nolla-Salas A Sitges-Serra C Leon-Gil Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU Intensive Care Med 23 1997 23 30
5. SB Wey M Mori MA Pfaller RF Woolson RP Wenzel Hospital-acquired candidemia. The attributable mortality and excess length of stay Arch Intern Med 148 1988 2642 2645
6. SK Fridkin WR Jarvis Epidemiology of nosocomial fungal infections Clin Microbiol Rev 9 1996 499 511
7. WE Trick SK Fridkin JR Edwards RA Hajjeh RP Gaynes National Nosocomial Infections Surveillance System Hospitals Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999 Clin Infect Dis 35 2002 627 630
8. B Almirante D Rodriguez BJ Park Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003 J Clin Microbiol 43 2005 1829 1835
9. LR Asmundsdottir H Erlendsdottir M Gottfredsson Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland Scand J Infect Dis 37 2005 111 120
10. CC Hung YC Chen SC Chang KT Luh WC Hsieh Nosocomial candidemia in a university hospital in Taiwan J Formos Med Assoc 95 1996 19 28
11. AS Kao ME Brandt WR Pruitt The epidemiology of candidemia in two United States cities: results of a population-based active surveillance Clin Infect Dis 29 1999 1164 1170
12. KB Laupland DB Gregson DL Church T Ross S Elsayed Invasive Candida species infections: a 5 year population-based assessment J Antimicrob Chemother 56 2005 532 537
13. E Poikonen O Lyytikaeinen VJ Anttila P Ruutu Candidemia in Finland, 1995–1999 Emerg Infect Dis 9 2003 985 990
14. AN Sofair GM Lyon S Huie-White Epidemiology of community-onset candidemia in Connecticut and Maryland Clin Infect Dis 43 2006 32 39
15. KW Garey M Rege MP Pai Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 43 2006 25 31
16. BJ Kullberg JD Sobel M Ruhnke Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 2005 1435 1442
17. ER Kuse P Chetchotisakd CA da Cunha Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527
18. J Mora-Duarte R Betts C Rotstein Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
19. PG Pappas CM Rotstein RF Betts Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 2007 883 893
20. AC Reboli C Rotstein PG Pappas Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482
21. JH Rex JE Bennett AM Sugar A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute N Engl J Med 331 1994 1325 1330
22. JH Rex PG Pappas AW Karchmer A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 2003 1221 1228
23. T Buchner W Fegeler H Bernhardt Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators Eur J Clin Microbiol Infect Dis 21 2002 337 352
24. H Chen KJ Suda RS Turpin MP Pai DT Bearden KW Garey High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis CurrMed Res Opin 23 2007 1057 1065
25. A Böhme M Ruhnke D Buchheidt Treatment of fungal infections in hematology and oncology—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol 82 suppl 2 2003 S133 S140
26. R Herbrecht U Fluckiger B Gachot P Ribaud A Thiebaut C Cordonnier Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients Eur J Cancer Suppl 5 2007 49 59
27. PG Pappas JH Rex JD Sobel Guidelines for treatment of candidiasis Clin Infect Dis 38 2004 161 189
28. O Tuil Y Cohen An open comparative multicenter study of intravenous (IV) itraconazole versus iv fluconazole in the treatment of candidemia in non-neutropenic patients Crit Care 7 2003 63 64
29. RK Mondal SC Singhi A Chakrabarti J Murlidharan Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study Pediatr Crit Care Med 5 2004 561 565
30. SC Singhi TC Reddy A Chakrabarti Oral itraconazole in treatment of candidemia in a pediatric intensive care unit Indian J Pediatr 71 2004 973 977
31. JA Vazquez DJ Skiest L Nieto A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS Clin Infect Dis 42 2006 1179 1186
32. EJ Anaissie RO Darouiche D Abi-Said Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature Clin Infect Dis 23 1996 964 972
33. EJ Anaissie SE Vartivarian D Abi-Said Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study Am J Med 101 1996 170 176
34. MH Nguyen JE Peacock Jr DC Tanner Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study Arch Intern Med 155 1995 2429 2435
35. P Phillips S Shafran G Garber Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group Eur J Clin Microbiol Infect Dis 16 1997 337 345
36. DW Bates L Su DT Yu Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis 32 2001 686 693
37. S Harbarth SL Pestotnik JF Lloyd JP Burke MH Samore The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy Am J Med 111 2001 528 534
38. CB Miller EK Waller HG Klingemann Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients Bone Marrow Transplant 33 2004 543 548
39. JR Wingard P Kubilis L Lee Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis Clin Infect Dis 29 1999 1402 1407
40. RC Matthews JP Burnie Human recombinant antibody to HSP90: a natural partner in combination therapy Curr Mol Med 5 2005 403 411
41. JI Ito R Hooshmand-Rad Treatment of Candida infections with amphotericin B lipid complex Clin Infect Dis 40 suppl 6 2005 S384 S391
42. L Ostrosky-Zeichner KA Marr JH Rex SH Cohen Amphotericin B: time for a new ‘gold standard’ Clin Infect Dis 37 2003 415 425
43. MJ DiNubile RJ Lupinacci KM Strohmaier CA Sable NA Kartsonis Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial J Crit Care 22 2007 237 244
44. J Pachl P Svoboda F Jacobs A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis Clin Infect Dis 42 2006 1404 1413